Psoriasis: disease severity linked to worse outcomes in real-world study

Takeaway

• Increasing disease severity by body surface area (BSA) affected and Investigator’s Global Assessment (IGA) is associated with worse patient-reported outcomes (PROs) in patients with psoriasis.

Why this matters

• This is the first study showing an association between severity measured by IGA, previously only used in clinical trials, and real-world PROs.

Key results

• For each increased level of BSA (moderate, severe, and very severe) and IGA (mild, moderate, and severe), Dermatology Life Quality Index (DLQI) score increased (P<.05 for all) and EuroQoL Visual Analogue Scale (EQ-VAS) score decreased (P<.05 for all).
• BSA levels of moderate, severe, and very severe were associated with Work Productivity and Activity Impairment (WPAI) score increases for "impairment while working" and "daily activities impaired," whereas very severe disease was associated with "work hours missed" and moderate and very severe diseases were associated with "work hours affected" (P<.05 for all).
• IGA levels of mild, moderate, and severe were associated with WPAI score increases for "daily activities impaired," whereas moderate and severe diseases were associated with "work hours missed," "impairment while working," and "work hours affected" (P<.05 for all).

Study design

• 1529 patients with psoriasis from the Corrona Psoriasis Registry were included.
• Funding: Corrona; Novartis

Limitations

• Cross-sectional study.